American CryoStem Corporation (CRYO) Research

American CryoStem Corporation (ACSC) specializes in the development, commercialization, and licensing of technologies derived from adipose (fat) tissue, primarily for applications within regenerative and personalized medicine. Among its key offerings is the CELLECT system, designed to streamline tissue sample collection, transportation, and storage for medical practitioners. The company also provides the ATGRAFT service, a comprehensive solution for harvesting, processing, and preserving adipose tissue, enabling physicians to offer patients versatile options for tissue products and cellular banking. Complementing these are ATCELL, a line of proprietary adipose-derived stem cells, and ACSelerat cell culture media, specifically formulated to promote the growth of human stromal cells. Furthermore, American CryoStem extends its expertise through contract manufacturing services for specific formulations, including Autokine-CM, an anti-aging topical product, and a unique autologous skin care range. Founded in 1987, American CryoStem Corporation is headquartered in Eatontown, New Jersey.

Market snapshot

Symbol
CRYO
Price
$0.00
Day change
-99.75%
Market cap
$4.4K
P/E ratio
-0.00x
52-week range
1.0E-4-0.175
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • American Bio Medica Corporation (ABMC)
  • Acacia Diversified Holdings, Inc. (ACCA)
  • Allied Healthcare Products, Inc. (AHPIQ)
  • Gene Biotherapeutics, Inc. (CRXM)
  • DermTech, Inc. (DMTKQ)
  • EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
  • ER Urgent Care Holdings, Inc. (ERUC)
  • GeneThera, Inc. (GTHR)

Recent insider activity

  • ARNONE JOHN S — A-Award (800000 shares) on 2012-09-04
  • Dudzinski Anthony Francis — A-Award (580000 shares) on 2012-09-04
  • ARNONE JOHN S — trade (0 shares) on 2011-04-21
  • Dudzinski Anthony Francis — trade (0 shares) on 2011-04-21
  • Neill Christopher Joseph — trade (0 shares) on 2011-04-21

Open American CryoStem Corporation (CRYO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.